National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Venetoclax (Venclyxto®) in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.


NCPE Assessment Process Complete
Rapid review commissioned 26/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 23/10/2018
Pre-submission consultation with Applicant 19/11/2018
Submission received from Applicant 03/01/2019
Preliminary review sent to Applicant 07/05/2019
NCPE assessment re-commenced 05/06/2019
Factual accuracy sent to Applicant 02/10/2019
NCPE assessment re-commenced 09/10/2019
NCPE assessment competed 08/11/2019
NCPE assessment outcome The NCPE recommends that venetoclax in combination with rituximab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*

Technical Summary Venetoclax

Plain English Summary Venetoclax


* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.